Report Detail

Pharma & Healthcare Global Meningioma Drug Market Insights, Forecast to 2025

  • RnM2897235
  • |
  • 12 February, 2019
  • |
  • Global
  • |
  • 115 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

The global Meningioma Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Meningioma Drug market based on company, product type, end user and key regions.

This report studies the global market size of Meningioma Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Meningioma Drug in these regions.
This research report categorizes the global Meningioma Drug market by top players/brands, region, type and end user. This report also studies the global Meningioma Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Arno Therapeutics Inc
AstraZeneca Plc
Boehringer Ingelheim GmbH
Eli Lilly and Co
Genentech Inc
GlaxoSmithKline Plc
Merck & Co Inc
Merck KGaA
Novartis AG
Ono Pharmaceutical Co Ltd
Pharma Mar SA
Progenics Pharmaceuticals Inc

Market size by Product
Abemaciclib
Afatinib Dimaleate
AR-42
Avelumab
Others
Market size by End User
Hospital
Clinic
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Meningioma Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Meningioma Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Meningioma Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Meningioma Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Meningioma Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Meningioma Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


Table of Contents

    1 Study Coverage

    • 1.1 Meningioma Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Meningioma Drug Market Size Growth Rate by Product
      • 1.4.2 Abemaciclib
      • 1.4.3 Afatinib Dimaleate
      • 1.4.4 AR-42
      • 1.4.5 Avelumab
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Meningioma Drug Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Meningioma Drug Market Size
      • 2.1.1 Global Meningioma Drug Revenue 2014-2025
      • 2.1.2 Global Meningioma Drug Sales 2014-2025
    • 2.2 Meningioma Drug Growth Rate by Regions
      • 2.2.1 Global Meningioma Drug Sales by Regions
      • 2.2.2 Global Meningioma Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Meningioma Drug Sales by Manufacturers
      • 3.1.1 Meningioma Drug Sales by Manufacturers
      • 3.1.2 Meningioma Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Meningioma Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Meningioma Drug Revenue by Manufacturers
      • 3.2.1 Meningioma Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Meningioma Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Meningioma Drug Price by Manufacturers
    • 3.4 Meningioma Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Meningioma Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Meningioma Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Meningioma Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Meningioma Drug Sales by Product
    • 4.2 Global Meningioma Drug Revenue by Product
    • 4.3 Meningioma Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Meningioma Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Meningioma Drug by Countries
      • 6.1.1 North America Meningioma Drug Sales by Countries
      • 6.1.2 North America Meningioma Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Meningioma Drug by Product
    • 6.3 North America Meningioma Drug by End User

    7 Europe

    • 7.1 Europe Meningioma Drug by Countries
      • 7.1.1 Europe Meningioma Drug Sales by Countries
      • 7.1.2 Europe Meningioma Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Meningioma Drug by Product
    • 7.3 Europe Meningioma Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Meningioma Drug by Countries
      • 8.1.1 Asia Pacific Meningioma Drug Sales by Countries
      • 8.1.2 Asia Pacific Meningioma Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Meningioma Drug by Product
    • 8.3 Asia Pacific Meningioma Drug by End User

    9 Central & South America

    • 9.1 Central & South America Meningioma Drug by Countries
      • 9.1.1 Central & South America Meningioma Drug Sales by Countries
      • 9.1.2 Central & South America Meningioma Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Meningioma Drug by Product
    • 9.3 Central & South America Meningioma Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Meningioma Drug by Countries
      • 10.1.1 Middle East and Africa Meningioma Drug Sales by Countries
      • 10.1.2 Middle East and Africa Meningioma Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Meningioma Drug by Product
    • 10.3 Middle East and Africa Meningioma Drug by End User

    11 Company Profiles

    • 11.1 Arno Therapeutics Inc
      • 11.1.1 Arno Therapeutics Inc Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Arno Therapeutics Inc Meningioma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Arno Therapeutics Inc Meningioma Drug Products Offered
      • 11.1.5 Arno Therapeutics Inc Recent Development
    • 11.2 AstraZeneca Plc
      • 11.2.1 AstraZeneca Plc Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 AstraZeneca Plc Meningioma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 AstraZeneca Plc Meningioma Drug Products Offered
      • 11.2.5 AstraZeneca Plc Recent Development
    • 11.3 Boehringer Ingelheim GmbH
      • 11.3.1 Boehringer Ingelheim GmbH Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Boehringer Ingelheim GmbH Meningioma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Boehringer Ingelheim GmbH Meningioma Drug Products Offered
      • 11.3.5 Boehringer Ingelheim GmbH Recent Development
    • 11.4 Eli Lilly and Co
      • 11.4.1 Eli Lilly and Co Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Eli Lilly and Co Meningioma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Eli Lilly and Co Meningioma Drug Products Offered
      • 11.4.5 Eli Lilly and Co Recent Development
    • 11.5 Genentech Inc
      • 11.5.1 Genentech Inc Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Genentech Inc Meningioma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Genentech Inc Meningioma Drug Products Offered
      • 11.5.5 Genentech Inc Recent Development
    • 11.6 GlaxoSmithKline Plc
      • 11.6.1 GlaxoSmithKline Plc Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 GlaxoSmithKline Plc Meningioma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 GlaxoSmithKline Plc Meningioma Drug Products Offered
      • 11.6.5 GlaxoSmithKline Plc Recent Development
    • 11.7 Merck & Co Inc
      • 11.7.1 Merck & Co Inc Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Merck & Co Inc Meningioma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Merck & Co Inc Meningioma Drug Products Offered
      • 11.7.5 Merck & Co Inc Recent Development
    • 11.8 Merck KGaA
      • 11.8.1 Merck KGaA Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Merck KGaA Meningioma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Merck KGaA Meningioma Drug Products Offered
      • 11.8.5 Merck KGaA Recent Development
    • 11.9 Novartis AG
      • 11.9.1 Novartis AG Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Novartis AG Meningioma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Novartis AG Meningioma Drug Products Offered
      • 11.9.5 Novartis AG Recent Development
    • 11.10 Ono Pharmaceutical Co Ltd
      • 11.10.1 Ono Pharmaceutical Co Ltd Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Ono Pharmaceutical Co Ltd Meningioma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Ono Pharmaceutical Co Ltd Meningioma Drug Products Offered
      • 11.10.5 Ono Pharmaceutical Co Ltd Recent Development
    • 11.11 Pharma Mar SA
    • 11.12 Progenics Pharmaceuticals Inc

    12 Future Forecast

    • 12.1 Meningioma Drug Market Forecast by Regions
      • 12.1.1 Global Meningioma Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Meningioma Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Meningioma Drug Market Forecast by Product
      • 12.2.1 Global Meningioma Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Meningioma Drug Revenue Forecast by Product 2019-2025
    • 12.3 Meningioma Drug Market Forecast by End User
    • 12.4 North America Meningioma Drug Forecast
    • 12.5 Europe Meningioma Drug Forecast
    • 12.6 Asia Pacific Meningioma Drug Forecast
    • 12.7 Central & South America Meningioma Drug Forecast
    • 12.8 Middle East and Africa Meningioma Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Meningioma Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Summary:
      Get latest Market Research Reports on Meningioma Drug . Industry analysis & Market Report on Meningioma Drug is a syndicated market report, published as Global Meningioma Drug Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Meningioma Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,084.90
      4,627.35
      6,169.80
      3,595.80
      5,393.70
      7,191.60
      605,670.00
      908,505.00
      1,211,340.00
      325,650.00
      488,475.00
      651,300.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report